跳至主要内容
临床试验/ISRCTN14411274
ISRCTN14411274进行中(未招募)未知

Assessment of an electronic system of the impact on inhaler skills and technique

niversity of Manchester0 个研究点目标入组 126 人开始时间: 2022年6月8日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
126

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Provision of signed and dated informed consent
  • 2. Willingness to comply with the study procedures and confirmed availability for the study duration
  • 3. Aged =16 years
  • 4. Self-reported asthma diagnosis and currently receiving treatment
  • 5. Regularly prescribed one of the following brands of inhaler and has been using it for at least 1-month prior to enrolment:
  • 5.1. Fostair pMDI (100 mcg Beclometasone/ 6 mcg Formoterol per dose; 200 mcg Beclometasone/ 6mcg Formoterol per dose); Chiesi Ltd
  • 5.2. Clenil Modulite pMDI (50 mcg, 100 mcg, 200 mcg or 250 mcg Beclometasone per dose); Chiesi Ltd
  • 5.3. Trimbow pMDI (87 mcg Beclometasone, 5 mcg Formoterol, 9 mcg Glycopyrronium per dose); Chiesi Ltd
  • 5.4. Seretide Evohaler pMDI (50 mcg Fluticasone/Salmeterol 25 mcg per dose; 125 mcg Fluticasone/Salmeterol 25 mcg per dose; 250 mcg Fluticasone/ Salmeterol 25 mcg per dose); GSK UK Ltd
  • 5.5. Flixotide Evohaler pMDI (50 mcg Fluticasone per dose; 125 mcg Fluticasone per dose; 250 mcg Fluticasone per dose); GSK UK Ltd
  • 6. Access to a smartphone or tablet device and willingness to use it to regularly assess inhaler technique for the study duration

排除标准

  • 1. Using a spacer to assist with using their inhaler
  • 2. Prescribed oral steroids for asthma in the preceding 1-month
  • 3. Medication is not self-administered
  • 4. Previous treatment for acute asthma in an IC

研究者

发起方
niversity of Manchester

相似试验